Project Name: Greater Manchester Cancer Care Alliance -Cancer Care Coordinators within Breast Oncology services
Project Summary:
The Collaborative Working Project (“CWP”) aims to maximise efficiency to optimise workforce capacity within the Greater Manchester (“GM”) breast cancer (“BC”) oncology service with the creation of a new dedicated workforce role of four Breast cancer care coordinators for two years. The intention is to maximise efficiency of clinical appointments that will improve the pathway for patients providing a more efficient and co-ordinated approach to their care.
Planned Milestones:
Milestone | Description |
---|---|
1 | Kick off meeting |
2 | Project lead to work up the job spec, protocols, workflow and recruitment of the cancer care coordinators and Project Manager |
3 | Confirmation of the 4 Breast Cancer care coordinators employment of; on-boarding and familiarisation; Implement in-patient strategies/protocols and procedures governing the clinical operations of the Breast Cancer Service. |
4 | Novartis SIM to conduct Reimagining Care Pathways for the GM SACT delivery service which is provided by the Christie oncology team |
5 | Carry out 3 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above. |
6 | Carry out 6 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above. |
7 | Project Manager to Network with the other 20 Cancer Care alliances to share the interim outputs of the service redesign |
8 | Carry out 9 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above. |
9 | Carry out 12 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above. |
10 | Carry out 15 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above. |
11 | Carry out 18 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above |
12 | Carry out 21 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above. |
13 | Carry out 24 months of clinical operations according to the developed protocols, The Christie to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria” section above |
14 | Develop business case to support future funding by the The Christie to continue with the service. Submit final CWP Develop with Novartis within 2 months from completion of the clinical work for outcomes publishing in line with the |
Expected Benefits:
ANTICIPATED BENEFITS FOR PATIENTS
- Named nurse co-ordinating BC care will improve patient experience of the BC service by coordinating the patients Cancer care appointments
- More streamlined pathway to improve the patient experience and limit visits to the hospital
ANTICIPATED BENEFITS FOR THE ORGANISATION(S)
- Workforce efficiency and optimisation by removing administrative burden from clinical staff and coordinating patient care
- Increased clinic efficiency by ensuring all up to date tests results are available at the right time
- Increase the overall quality of care and improve equity of access to specialist care for patients with BC requiring treatment initiation, evaluation, and monitoring
- Provide a single point of contact for patients, thereby reducing the potential for unplanned calls being received by the wider clinical team
- Free up consultant capacity for clinical activities that are unique to their skillset
- CWP would highlight GM cancer Care Alliance and The Christies as an exemplar in service re-design of worksforce optimisation and sustainability
ANTICIPATED BENEFITS FOR NOVARTIS
- Better understanding of overall HCP and patient needs
- Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations
Start Date & Duration: October 2023 for 32 months
UK2310115503